Find out if the deal Omeros announced is enough of a reason to buy this stock.Shares of Omeros (OMER 153.90%) finished Oct. 14's trading session at $4.10 per share. When the market opened on Oct. 15, the stock was up by 181$11.52 per share.It was a deal with the Danish drugmaker that markets Ozempic and Wegovy that moved Omeros' stock price. Novo Nordisk (NVO 0.11%) will give the clinical-stage drugmaker $340 million upfront for exclusive global rights to develop and commercialize zaltenibart. This is ...